Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP983277.RA5jsKgjhT-AuU6WHZT8NpzlnwUqQ8bSu29BJbkmwrrsc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP983277.RA5jsKgjhT-AuU6WHZT8NpzlnwUqQ8bSu29BJbkmwrrsc130_assertion type Assertion NP983277.RA5jsKgjhT-AuU6WHZT8NpzlnwUqQ8bSu29BJbkmwrrsc130_head.
- NP983277.RA5jsKgjhT-AuU6WHZT8NpzlnwUqQ8bSu29BJbkmwrrsc130_assertion description "[Thus, access to HCV treatment is of utmost importance in IL28B CC carriers, in whom treatment response is better and in whom progression to cirrhosis might occur more rapidly.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP983277.RA5jsKgjhT-AuU6WHZT8NpzlnwUqQ8bSu29BJbkmwrrsc130_provenance.
- NP983277.RA5jsKgjhT-AuU6WHZT8NpzlnwUqQ8bSu29BJbkmwrrsc130_assertion evidence source_evidence_literature NP983277.RA5jsKgjhT-AuU6WHZT8NpzlnwUqQ8bSu29BJbkmwrrsc130_provenance.
- NP983277.RA5jsKgjhT-AuU6WHZT8NpzlnwUqQ8bSu29BJbkmwrrsc130_assertion SIO_000772 21592993 NP983277.RA5jsKgjhT-AuU6WHZT8NpzlnwUqQ8bSu29BJbkmwrrsc130_provenance.
- NP983277.RA5jsKgjhT-AuU6WHZT8NpzlnwUqQ8bSu29BJbkmwrrsc130_assertion wasDerivedFrom befree-20150227 NP983277.RA5jsKgjhT-AuU6WHZT8NpzlnwUqQ8bSu29BJbkmwrrsc130_provenance.
- NP983277.RA5jsKgjhT-AuU6WHZT8NpzlnwUqQ8bSu29BJbkmwrrsc130_assertion wasGeneratedBy ECO_0000203 NP983277.RA5jsKgjhT-AuU6WHZT8NpzlnwUqQ8bSu29BJbkmwrrsc130_provenance.